Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Drug Control and Registration in Thailand - 2010

392 views

Published on

By Siriporn Chawanon, Pharmacist at the Drug Control Division, Thai Food and Drug Administration

Published in: Food
  • Be the first to comment

Drug Control and Registration in Thailand - 2010

  1. 1. 8/12/2010 1 DRUG CONTROL AND REGISTRATION SIRIPORN CHAWANON Pharmacist, professional level Drug Control Division Thai Food and Drug Administration
  2. 2. 8/12/2010 2 OUTLINE • Drug Control System • The Organization of Drug Control Division • Drug Licensing and Registration •Drug Registration system •Safety Monitoring Program
  3. 3. 8/12/2010 3 DRUG CONTROL SYSTEM MINISTRY OF PUBLIC HEALTH FOOD AND DRUG ADMINISTRATION (FDA) DEPARTMENT OF MEDICAL SCIENCES PROVINCIAL HEALTH OFFICES THAI FDA PRE-MARKETING: LICENSING DRUG REGISTRATION POST-MARKETING: INSPECTION SURVEILLANCE ADR MONITORING
  4. 4. 8/12/2010 4 The Organization Chart of Drug Control Division Drug Control Division Policy and System Development Section Generic Drug Section New Drug Section Biological Product Section Herbal and Traditional Drug Section International Affairs and IND section Advertising Control Section National List of Essential Medicines Development Section Veterinary Drug Section Generic Product industry and Intellectual Property Section Administrative Sub-division
  5. 5. 8/12/2010 5 Thai Regulatory System The legislative basis of this system is the Drug Act BE 2510 (1967) and amendments
  6. 6. 8/12/2010 6 Thai Regulatory System The Drug Act provides that decisions of the Secretary-General, FDA, be made with advice of a Drug Board made up of principal relevant Departmental Directors General in the MoPH as well as representatives from related organizations, plus five to nine drug experts. The Drug Board meets monthly and may give recommendations or opinions on licensing and registration decisions such as approved, withdraw or suspend the licenses.
  7. 7. 8/12/2010 7 Licensing The drug Act requires that persons who wish to sell, produce, or import drugs into Thailand have to obtain a license from the FDA.
  8. 8. 8/12/2010 8 RegistrationRegistration • Qualified person: Authorized licensees • To ensure efficacy safety and quality of drugs • Upon receipt of Drug Registration Certificate, the drug can be lawfully marketed.
  9. 9. 8/12/2010 9 DRUG REGISTRATION AND APPROVAL New Drugs and New Generic Drugs New Drug Section (for human uses) Generic Drugs (for human uses) Generic Drug Section Biological Products Biological Product Section (for human or veterinary uses) Veterinary Drugs Veterinary and Pharmaceutical chemicals Section (not include Biological Products and Traditional and Herbal Drugs) Traditional and Herbal Drugs Traditional and Herbal Medicine Section (for human or veterinary uses)
  10. 10. 8/12/2010 10 DRUG REGISTRATION PROCESS Applicants: Only authorized licensees are qualified to apply for product registration. Manufacturing plants :GMP compliance 2 steps: Step 1: Application for permission to manufacture or import of drug samples – One Stop Service Center Step 2: Application for product registration approval
  11. 11. 8/12/2010 11 Flow Chart of Drug Review Process ApplicantApplicant ApplicationApplication Pre-filing screening ReviewPre-filing screening Review Review by Experts/Subcommittee/CommitteeReview by Experts/Subcommittee/Committee Make Decision by FDAMake Decision by FDA ApprovedApproved RevisedRevised RejectedRejected [Completeness Review] [Technical Review]
  12. 12. 8/12/2010 12 Thai FDA Classified modern medicine into 3 categories : New drugs New generic drugs: Pharmaceutical products with the same active ingredients, doses and dosage forms as those of new compounds (new drugs) registered after 1992 but manufactured by different manufacturers Generic drugs.
  13. 13. 8/12/2010 13 Thai FDA Classified modern medicine into 3 categories : New drugs: registrations is the most stringent of all require a complete set of product dossiers Generic drugs. The registrations require basically dossiers on product manufacturing and quality control together with product information. New generic drugs: In addition to the required dossiers for generic submission, the new generic registrations require dossiers of bioequivalence studies as well as literature documents for supporting safety and efficacy
  14. 14. 8/12/2010 14 ASEAN HARMONIZATION PRODUCT i.e. ACTR , ACTD 4 Technical Guidelines (1) Analytical Validation guideline (2) BA/BE Studies guideline (3) Process Validation guideline (4) Stability Study .
  15. 15. 8/12/2010 15 Process of New Drug Registration Track 1 : Standard Review 210 - 280 working days Track 2 : Accelerated or Priority Review (Drugs for public health problems / life threatening) 100-130 working days
  16. 16. 8/12/2010 16 Process of New Generic Drug Registration Track 1 : Standard Review 110 working days Track 2 : Accelerated or Priority Review (Drugs for public health problems / life threatening) 70 working days
  17. 17. 8/12/2010 17 New Drug Registration (ASEAN Harmonization) ASEAN Common Technical Dossiers (ACTD) Documents to be submitted 4 Parts Part 1: Administrative Data and Product Information Part 2: Quality Document Part 3: Nonclinical Document Part 4: Clinical Document
  18. 18. 8/12/2010 18 New Drug Registration System New Drug Step I Experts/Subcommittee Approval Conditional approval SMP & Limited distribution (2 yrs) Unconditional approval Step II Voluntary Spontaneous ADR Reporting System
  19. 19. 8/12/2010 19 Conditional Approval Safety Monitoring Program (SMP) will be conducted for approx. 2 years. Drug packages must bear labeling to show conditional approval status. Triangle shows monitoring status. Specially-control drug Limited distribution only through medical institutes or hospitals should monitori ng
  20. 20. 8/12/2010 20 Objectives: • To confirm the drug safety in Thai patients • To generate earlier safety signals and gather more safety information of new drugs before granting and unconditional approval. • To more rigorously control the usage of new drugs Why SMP?
  21. 21. 8/12/2010 21 Objectives: • To encourage physicians, pharmacist and other health professionals to have more concerns on the safety of new drugs and their usage. Why SMP? (2)
  22. 22. 8/12/2010 22 • Capacity building on drug evaluation and registration in order to be prepared for ASEAN Pharmaceutical Harmonization and WHO assessment of regulartory system. • Collaboration and communication links with other NRAs in order to strengthen professional competence and exchange information (MOU with TGA, US FDA Regulator Training Program for vaccine) • BE study submitted for registration should be conducted in compliance with the ICH GCP as well as GLP standard. What Have Been Currently Done ?
  23. 23. 8/12/2010 23 • Encourage current and new domestic manufacturer to upgrade their quality standard. • The proposed revision of Drug Act is expected to bring about better drug regulatory implications • One Stop Service Center has been established for submitted applications which can be processed and approved within a short time period. What Have Been Currently Done ?
  24. 24. 8/12/2010 24 • Maintain a balance between ensuring a product is safe, efficacious and of good quality and not delaying public access to the products.by Clearly separate the tracks of registration submission into standard review and priority review and Reduce the timelines for each steps were announced. What Have Been Currently Done ?
  25. 25. 8/12/2010 25 1. The fast track pathway for the emergent medicine, such as, neoplastic, H.I.V., antituberculous drug, antiviral vaccine, can reduce the consideration period from 280 working days to 130 working days. 2. Thailand's MoPH issued a compulsory license for HIV drug (EFFAVIRENZE, lopinavir/ritronavir) and drug for other diseases with public health consequences such as cancer or other chronic diseases (letrozole Imatinib errotinib docetaxel clopidogrel) The proposed policies to promote the accessibility of the medicine, which can solve the public health’s problem
  26. 26. 8/12/2010 26 3. The personnel’s efficiency should be more developed and improve competence 4. the ASEAN Economic Ministers signed the ASEAN Sectoral Mutual Recognition Arrangement (MRA) for Good Manufacturing Practice (GMP). The proposed policies to promote the accessibility of the medicine, which can solve the public health’s problem
  27. 27. 8/12/2010 27 THANK YOU FOR YOUR ATTENTION THANK YOU FOR YOUR ATTENTION www.fda.moph.go.th E-mail: be.study@gmail.com www.fda.moph.go.th E-mail: be.study@gmail.com
  28. 28. Asian Food Regulation Information Service is a resource for the food industry. We have the largest database of Asian food regulations in the world – and it’s FREE to use. We publish a range of communication services (free and paid), list a very large number of food events and online educational webinars and continue to grow our Digital Library. Feel free to contact us anytime to talk about your specific requirements, offer comments, complaints or to compliment us. We look forward to hearing from you soon! www.asianfoodreg.com adrienna@asianfoodreg.com

×